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Background: Thyroid hormone is crucial in the development of different organs, particularly the brain. MCT8 is a
specific transporter of triiodothyronine (T3) hormone and MCT8 gene mutations cause a rare X-linked disorder
named MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome, characterized by psychomotor retardation
and hypotonia. Typically, elevation of T3 and delayed myelination in cerebral magnetic resonance imaging are found.
Case presentation: We present a 24-month-old boy, born from non-consanguineous healthy parents, with severe
motor and cognitive delay and global hypotonia, being unable to hold head upright or sit without support. Deep
tendon reflexes were absent bilaterally at the ankles. T3 was elevated and thyroxine slightly decreased, consistent
with MCT8 deficiency. Genetic studies confirmed the diagnosis.
Conclusions: Although a rare disease (MCT8 mutations have been reported in about 50 families all around the
world), we illustrate the importance of excluding Allan-Herndon-Dudley syndrome in the evaluation of floppy male
infants with development delay, without history of perinatal asphyxia. The simple evaluation of thyroid status,
including T3, T4 and TSH can guide the diagnosis, avoiding a number of useless, expensive and invasive investigations
and allowing appropriate genetic counseling to the affected families.
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Thyroid hormone (TH) plays a major role in the growth
and development of multiple tissues, in particular the
brain [1,2]. The effects of TH are determined by the
intracellular concentration of triiodothyronine (T3) avail-
able to bind to its nuclear receptor [1,3-5]. Recently,
monocarboxylate transporter 8 (MCT8) has been identi-
fied as an active and specific TH transporter that plays a
critical role in the transport of T3 across the blood–
brain barrier and in T3 uptake into neuronal cells [3,6,7].
Different mutations in MCT8 are responsible for a rare
X-linked condition, Allan-Herndon-Dudley syndrome
(AHDS) that is characterized by global hypotonia that
progresses into spasticity with severe psychomotor delay
[8]. All affected males present with elevated serum levels* Correspondence: filipa.a.rodrigues@gmail.com
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unless otherwise stated.of T3, low to below normal serum levels of prohormone
thyroxine (T4) and thyroid stimulating hormone (TSH)
in normal range [8,9].
The authors describe a 24 month-old-boy with severe
hypotonia during the first year of life, emphasizing the
clinical, laboratory and neuroradiological findings that
prompted the genetic study that confirmed the mutation
in MCT8 gene.Case presentation
We present a 24-month-old male patient, second child
of non-consanguineous parents. During pregnancy thy-
roid hormone levels of the mother showed low free T4
level (8.75 pmol/L; normal values 9.39 - 28.31) and nor-
mal TSH level (3.17 mUI/L, normal values 0.25 - 5.0).
Delivery was uneventful. Gestational age was 38 weeks
and the Apgar score in the first and fifth minutes was 9
and 10 respectively. His birth weight and length were
normal and the head circumference (38 cm) was above
2SD. Neonatal period was normal.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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son with the diagnosis of cerebral palsy with no history
of any risk factors (prenatal, gestational or postnatal).
The father and paternal grandmother have a sensori-
neural hearing loss, which occurred at around the age of
forty.
From the age of 3 months global hypotonia and poor
head control became evident. A rehabilitation program
was started without any satisfactory improvement. At
the age of 12 months the severe hypotonia persisted,
without any improvement in head control. The child
was able to grasp objects and bring both hands to the
midline, but with significant difficulty. No pyramidal
tract involvement was described. At this age, the
pediatrician described the child as active and reactive
to stimuli, with good visual contact, normal social smile
and appropriate interaction between the child and his
parents. At that time, cerebral magnetic resonance im-
aging (MRI) was performed and revealed an enlargement
of the subarachnoid spaces, without any description of
white matter disorder. Brainstem auditory evoked poten-
tial was normal. Assessment of visual evoked potentials
showed evidence of a conduction delay in central optical
pathways; fundoscopy was normal. No alterations were
detected in the basic laboratory and metabolic investiga-
tions performed (serum electrolytes, renal and hepatic
function, creatine kinase, biotinidasis, urate, lactate and
pyruvate, ammonia, urinary organic acid, plasma and
urinary ammino acid).
By the age of 21 months the patient was referred to
our Neuromuscular Pediatric Unit due to severe motor
and cognitive delay. At this first visit the patient showed
global and severe hypotonia, being unable to hold the
head upright and to sit without support (Figure 1).Figure 1 Clinical features. The child at 24 months of age showing global
support, and to hold the head upright.When supine, the patient demonstrated brief episodes of
mild dystonic movements and hypertonic posturing of
the limbs, triggered by stress conditions or sensitive
stimulus. The myotatic reflex was slightly increased in
triceps surae muscle and Babinski sign was observed.
Deep tendon reflexes were absent at the Achilles tendon
bilaterally. Eye contact and visual tracking of human face
were poor. He was responsive to sounds but was unable
to speak.
At the age of 23 months he developed myoclonic jerks
characterized by flexion of the neck and upper limbs,
lasting no longer than few seconds, ocurring up to twice
or three times per day. Initially these epileptic seizures
improved with the administration of sodium valproate;
however they have reappeared, up to three to four times
a day, in spite of the treatment with sodium valproate,
levetiracetam and vigabatrin. The latest electroencepha-
lograms revealed polyspike and wave discharges that are
widely spread over both hemispheres of the brain with a
slow background rhythm. Electromyography and neuro-
graphy were normal. Electroretinogram was normal.
Cerebral MRI was repeated at 24 months of age, which
demonstrated a delay of myelination (Figure 2).
After repeating some laboratory tests, alterations
on thyroid function revealed elevated free T3 level
(4.84 nmol/L, normal values 0.63-3.90), low free T4 level
(8.2 pmol/L, normal values 9.1 - 25.0) and normal TSH
level (3.54 mUI/L, normal values 0.3 - 4.5). Given this
hormonal pattern, the existence of a deficit in T3 carrier
was considered as a potential diagnosis. To investigate
this hypothesis direct sequencing of the SLC16A2 gene
was performed, revealing 26 base duplication in exon 2.
This gene mutation has not been described previously
and causes a Val254Glu substitution followed by a framehypotonia, hypertonic posture of the limbs, incapacity to sit without
Figure 2 Cerebral magnetic resonance image. Axial, T2-fast spin echo sequence (a) shows a significative alteration in white matter substance
in the centrum semiovale, frontoparietal, parieto-occipital and subcortical regions, compatible with a marked delay in myelination; and cerebral
magnetic resonance spectrometry (b) demonstrates a low N-acetyl aspartic peak.
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(Exon 2 c.735_760dup p.Val254Glufs*24). His mother
was subsequently confirmed to be a carrier for this dupli-
cation (Figure 3).
Discussion
This phenotype of severe X-linked psychomotor delay
was first described in 1944 and was eponymously named
Allan-Herndon-Dudley syndrome [10]. Afterwards, in
2004, the first mutations in MCT8 gene (SLC16A2)Figure 3 Electropherograms. The duplication found in exon 2 of MCT8 in
mother (bottom tracing), and the corresponding normal sequence (top trawere discovered by two distinct investigation groups
(Dumitrescu et al. and Friesema et al.), and neurological
findings of AHDS were explained by the resistance of T3
on entering the neuronal target cells, that leads to a clas-
sical thyroid profile found in all affected patients [8,9].
Currently, MCT8 mutations have been reported in about
50 families worldwide [4,11].
Diagnosis of AHDS in our patient is supported by: the
presence of an X-linked inheritance; the characteristic
thyroid hormonal pattern; the marked delay of myelinationthe patient (middle tracing), the sequence of the heterozygous
cing).
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the presence of the pathogenic mutation in the MCT8
gene. AHDS shows a broad and heterogeneous clinical
spectrum according to the type of mutation and its impact
on the protein synthesis stage. Our patient fits well with
the most severe phenotype [12].
One of the main features of AHDS, also known as
MCT8 deficiency, is the marked global hypotonia and
difficulties maintaining the head up right, recognized as
”limber neck” (Figure 1), evident since the first months
of life [13]. In the presence of a floppy infant, evaluation
of signs of CNS involvement is essential but not always
easy during the first year of life. In this case, normal eye
contact and social interaction by the age of 12 months,
in addition to the lack of deep tendon ankle reflexes,
made peripheral neuromuscular involvement an import-
ant hypothesis to exclude. The absence of signs of CNS
involvement during the first year of life could have re-
sulted in a muscle biopsy in order to exclude a congeni-
tal myopathy or other muscle disorder. However, the
presence of spasticity and abnormal movements during
the second year of life make it clear that this investiga-
tion was not warranted.
During the evaluation of a hypotonic infant, the cere-
bral MRI is a helpful tool for detecting CNS abnormal-
ities [11]. The difficulty in interpreting a cerebral MRI
during the first year of life leads to different descriptions
of the white matter abnormalities ranging from delayed
myelination to hypomyelination, which can delay the
diagnosis [11,12,14,15]. Despite the static or even deteri-
orating clinical picture for these patients, several studies
confirm that the major neuroradiological feature of
this disease is the marked delayed myelination [14,15].
Many of these children were described as a “Pelizaeus–
Merzbacher–Like Disease” because they had a similar
phenotype without the identification of PLP1 mutation.
This is a differential diagnosis that needs to be considered
and the cerebral MRI is an important tool. In Pelizaeus–
Merzbacher disease we find a hypomyelination (same pat-
tern of deficient myelination on 2 MRIs at least 6 months
apart in a child older than 1 year) while in AHDS, a correct
MRI interpretation will show a progression of myelination,
even if slow [11,14]. In our case the relatively low N-acetyl
aspartic peak in the cerebral magnetic resonance spectros-
copy also supports the hypothesis of delayed myelination
(Figure 2) [16].
The neurological manifestations of this disease are
quite complex. The axial hypotonia persists throughout
adulthood, while the hypotonia of the limbs progresses
to spasticity and dystonic posturing [3,13]. The age of
onset of extrapyramidal symptoms is not clear in the
literature and it seems essential for us to suspect of
AHDS even before these signs appear [13]. Other im-
portant features are the inability to sit, stand or walkindependently, the severe mental retardation with lack of
speech development and rudimentary communicative
skills [13,17]. A quarter of the patients will have seizures
that are usually responsive to anticonvulsant therapy [13].
As already mentioned all affected males with MCT8 mu-
tations exhibit a typical thyroid profile which makes it cru-
cial to request these hormones, including T3 early in the
investigation [3,8,9]. Mean serum T4 and free T4 are nor-
mal or slightly decreased, TSH is normal or mildly in-
creased and serum T3 and free T3 are markedly elevated
[3,8,9,14]. This will help the clinician to avoid unnecessary
tests and to pursue a specific genetic analysis of SLC16A2
for a definitive diagnosis. There is another medical condi-
tion with the same thyroid hormonal pattern, that can be
found in a hypotonic infant and that is due to a mutation
in the thyroid hormone receptor α gene (TRα1). This
condition has a similar presentation in the first months of
life; however older infants and children present with
a phenotype very different from AHDS, developing the
classic features of hypothyroidism (growth retardation,
skeletal dysplasia, reduced muscle tone, constipation) and
only a mild cognitive impairment [18].
Some AHDS patients have been treated with TH sup-
plementation, propylthiouracil or diiodothyropropionic
acid; the last two result in better thyroid function tests,
but without any improvement of motor or cognitive skills
[19-21]. Up to this moment, we can only offer symptom-
atic treatment to these patients, such as rehabilitation
therapies, antispasticity, antidystonic and anticonvulsant
medication, nutritional and orthopedic management
[13,20,22]. Genetic counseling should be offered to the
family as soon as the diagnosis is recognized as is the case
with all other X-linked recessive conditions: if the mother
has SLC16A2 mutation, boys will have a 50% risk of being
affected, whereas girls will have a 50% chance of being a
carrier of the mutation [13,22]. The genetic test was sug-
gested to be undertaken by the patient’s cousin but unfor-
tunately his parents have systematically refused.
Conclusion
Through this clinical report we demonstrate the import-
ance of excluding AHDS in the initial laboratory evaluation
of floppy male infant, without history of perinatal asphyxia,
by the simple exploration of the thyroid hormone status,
including T3. In spite of the absence of an effective treat-
ment for this disease, an early diagnosis can avoid a num-
ber of useless, expensive and invasive investigations and
permit correct genetic counseling to the affected families.
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